METTL2B

Across TCGA pan-cancer cohorts, METTL2B Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated METTL2B data layer compared with 27 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher METTL2B Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated METTL2B expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

LIHC, UCEC, and LUAD are the cancer types where METTL2B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	All	0.173	0.779	<.001	18	view →
UCEC	DFS	Median	All	1.000	0.630	.023	8	view →
LUAD	OS	Median	All	0.323	0.834	.003	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

METTL2B–LIHC (OS)

Open the LIHC breakdown →